Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

The company expects to enroll approximately 160 patients across 40 centers worldwide.
  • Kuvan Outcomes Study: PKU-016, a randomized, placebo-controlled, 13-week Kuvan outcomes study is ongoing.  Endpoints include clinically validated measures of neuropsychiatric symptoms and if successful, may enable a label amendment.  
  • Hand-Held Blood Phe Monitor: Several other programs are underway to expand and protect the market and to improve the ability of healthcare providers and patients to better manage PKU.  These programs include a state-of-the-art handheld device to measure blood Phe levels in PKU patients. Regulatory approval and commercial availability of the handheld blood Phe monitor are expected in late 2011.
  • Firdapse: BioMarin expects to initiate a Phase III trial for LEMS in the U.S. in the second quarter of 2011.  If successful, NDA submission is expected in the first half of 2012, followed by approval by the end of 2012.

  • Mid-Stage Clinical Programs

  • PEG-PAL for PKU: Top-line results for the Phase II study, including a study comparing daily and weekly dosing and a formulation study are expected in mid-2011.  The company expects to initiate a Phase III trial in the first quarter of 2012.

  • Early-Stage Clinical Programs

  • BMN-673 (PARP inhibitor):  The company initiated a Phase I/II trial in January 2011.  The trial is an open-label study of once daily, orally administered BMN-673 in up to 70 patients ages 18 and older with advanced or recurrent solid tumors.  The primary objective of the study is to establish the maximum tolerated dose of daily oral BMN-673 and to obtain preliminary efficacy data in an expanded cohort of patients with genetically-defined tumors.
  • BMN-701 for Pompe Disease: BioMarin initiated a Phase I/II trial in Pompe patients in January 2011.  The trial is an open-label study to ev
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
    2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
    3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
    4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
    5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
    6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
    7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
    8. BioMarin Announces Third Quarter 2010 Financial Results
    9. BioMarin to Host a Research and Development Day on October 19th
    10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    11. BioMarin to Present at the UBS Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
    (Date:9/17/2014)... -- An analysis done by the CVS Health Research ... new and expensive treatment for Hepatitis C introduced in ... months (May through August 2014) there has been a ... suggests another surge of patients will begin therapy when ... and shorter duration are introduced in the Fall. ...
    (Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
    Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
    ... Synteract, Inc ., a full-service contract ... training classes for CDISC , a global, ... the acquisition, exchange, submission and archive of clinical ... 21-24, 2012 at Synteract,s Carlsbad, Calif., headquarters. ...
    ... COLUMBUS, Ohio, Feb. 17, 2012  Chemical Abstracts Service ... Taylor & Francis, a leading publisher of scientific ... new experimental procedures for chemical reactions from three ... SciFinder®. (Logo: http://photos.prnewswire.com/prnh/20110418/MM84805 ) ...
    Cached Medicine Technology:Synteract Hosting CDISC Classes on Regulatory Data Standards, Feb. 21-24, in California 2CAS and Taylor & Francis Collaborate to Improve Scientists' Access to Published Research 2
    (Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
    (Date:9/17/2014)... (HealthDay News) -- A blood test that measures DNA ... a better assessment of the state of a man,s ... routinely, this blood test could reveal when treatment ... promoting tumor growth, the researchers suggested. "Our study ... advanced prostate cancer and often initially very effective started ...
    (Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
    (Date:9/17/2014)... Why are Asian Americans at higher risk of developing ... develop the disease at lower body weights? One part ... traditional high-fiber, low-fat Asian diets to current westernized diets, ... heritage, says George King, M.D., Senior Vice President and ... senior author of the study. , A Joslin randomized ...
    (Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace is ... on molecular diagnostics for conditions such as infectious diseases, ... IVD market value is projected to be worth around ... major drivers of the market’s growth include the shift ... by the explosion for raid and minimally-invasive diagnostic tools; ...
    Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
    ... countrymen safe drinking water within a matter of four ... // to make this possible. Most people living in ... water. ,Inaugurating a conference of ministers ... sanitation in states and union territories, the prime minister ...
    ... speak hundred words, these non-verbal communications is also found ... been a major cause of distress and may lead ... School of Medicine along with his colleagues from Indianapolis ... as reported in the Journal of General Internal Medicine ...
    ... Journal of the American Medical Association has published that ... continue their anti-depressant medication to avoid a relapse.// ... University and Massachusetts General Hospital, where 201 pregnant women ... not depressed during the course of the study. According ...
    ... Michael Horwin have launched the SV40 Cancer Foundation in ... 1999 from an SV40 positive brain tumor. // The ... encourage independent research and to facilitate clinical improvements." ... brain tumor that was caused by an active SV40 ...
    ... there is a definite link between disease and higher death rates ... the // data of 1,347 people aged about 56 in the ... ,The IQ of the volunteers was assessed by a written test ... scores follow a social trend and that the poorest socioeconomic groups ...
    ... revealed that a Husband’s comforting touch can be a ... the study, those who establish instant communication by reaching ... A handy tip on how human touch can alleviate ... feature of the study revealed that relief from a ...
    Cached Medicine News:Health News:Safe Drinking Water To Be Made Available 2Health News:Pregnancy Not An Antidote To Depression 2Health News:Handy Touch - A Wand to Bust Stressful Situations 2
    ... Nebulizer Disposable Prefilled 28%-100% FIO 2 1000ML ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
    Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
    ... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
    ... modified nebulizer setups to deliver CNT and ... your patient is critical? OMNI~MAX has everything ... Heliox rescue therapy. In severe obstructive disease, ... of care in hospitals across the nation. ...
    Medicine Products: